BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Baxano Announces Close of $30 Million Series C Funding


6/22/2010 6:28:45 AM

SAN JOSE, Calif., June 22 /PRNewswire/ -- Baxano, Inc. (www.baxano.com) today announced the closing of a $30 million Series C round of venture funding, led by new investor CMEA Capital. Funds were also contributed by new investors Kaiser Permanente Ventures and Affinity Capital Management and existing investors Prospect Venture Partners, Three Arch Partners, and Kearny Venture Partners.

The Baxano™ iO-Flex™ System is FDA-cleared and commercially available in selected markets. Proceeds from the Series C round of funding will support the US commercial launch and additional post-clearance clinical study of the iO-Flex System.

"We were very impressed by the progress that Baxano has made in making the iO-Flex System available to patients suffering from lumbar spinal stenosis. Complete decompression of involved nerve roots while preserving spinal stability can be clinically challenging with current surgical tools, often leading to suboptimal clinical outcomes and reoperations," stated Rod Altman, MD, Senior Partner, CMEA Capital. "Baxano's iO-Flex System is a unique opportunity to bring a safe and effective less-invasive solution to patients, physicians and payers."

"The closing of this round of financing launches the next phase of growth for Baxano. Adding our new investors to our extremely strong venture capital partners demonstrates our value proposition as a company," said Tony Recupero, President and CEO of Baxano, Inc. "We believe this round of investment further validates the potential value of the iO-Flex System for all stakeholders in today's cost-effective healthcare environment."

About Baxano, Inc.

Based in San Jose, CA, Baxano, Inc., (www.BAXANO.com) is focused on developing innovative solutions that restore spine function, preserve healthy tissue, and enable a better quality of life for patients. Baxano, Inc. is the developer of the iO-Flex™ System which is an advancement in surgical technology for central, lateral recess and foraminal lumbar stenosis. This unique technology uses thin, flexible instruments through an open exposure or a minimally invasive tube to provide precision lumbar decompression from the "inside out" ("iO"). This "over the wire" approach allows surgeons to address targeted impinging tissue with a non-implant, direct decompression, while preserving facet joint integrity. Up to four nerve roots may be decompressed through a single-point access using this system.

Note:

Baxano and iO-Flex are registered trademarks of Baxano, Inc.


Baxano
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES